Viatris ROE 2010-2024 | VTRS
Current and historical return on equity (ROE) values for Viatris (VTRS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Viatris ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-09-30 |
$-0.88B |
$19.79B |
-4.43% |
| 2024-06-30 |
$-0.65B |
$19.52B |
-3.20% |
| 2024-03-31 |
$-0.06B |
$20.01B |
-0.27% |
| 2023-12-31 |
$0.05B |
$20.47B |
0.26% |
| 2023-09-30 |
$1.83B |
$20.87B |
8.75% |
| 2023-06-30 |
$1.85B |
$20.84B |
9.04% |
| 2023-03-31 |
$1.90B |
$20.93B |
9.40% |
| 2022-12-31 |
$2.08B |
$21.07B |
10.32% |
| 2022-09-30 |
$0.80B |
$19.18B |
4.02% |
| 2022-06-30 |
$0.76B |
$19.81B |
3.72% |
| 2022-03-31 |
$0.17B |
$20.45B |
0.81% |
| 2021-12-31 |
$-1.27B |
$20.49B |
-6.02% |
| 2021-09-30 |
$-1.92B |
$21.14B |
-8.86% |
| 2021-06-30 |
$-2.05B |
$21.21B |
-10.48% |
| 2021-03-31 |
$-1.73B |
$21.42B |
-10.07% |
| 2020-12-31 |
$-0.67B |
$22.95B |
-4.58% |
| 2020-09-30 |
$0.27B |
$12.55B |
2.25% |
| 2020-06-30 |
$0.27B |
$11.75B |
2.34% |
| 2020-03-31 |
$0.06B |
$11.26B |
0.54% |
| 2019-12-31 |
$0.02B |
$11.88B |
0.14% |
| 2019-09-30 |
$0.05B |
$11.46B |
0.40% |
| 2019-06-30 |
$0.03B |
$11.90B |
0.28% |
| 2019-03-31 |
$0.24B |
$11.89B |
1.99% |
| 2018-12-31 |
$0.35B |
$12.17B |
2.85% |
| 2018-09-30 |
$0.55B |
$12.07B |
4.30% |
| 2018-06-30 |
$0.46B |
$12.21B |
3.52% |
| 2018-03-31 |
$0.72B |
$13.18B |
5.44% |
| 2017-12-31 |
$0.70B |
$13.31B |
5.44% |
| 2017-09-30 |
$0.87B |
$13.29B |
7.11% |
| 2017-06-30 |
$0.66B |
$12.83B |
5.57% |
| 2017-03-31 |
$0.53B |
$11.66B |
4.74% |
| 2016-12-31 |
$0.48B |
$11.12B |
4.41% |
| 2016-09-30 |
$0.26B |
$11.83B |
2.44% |
| 2016-06-30 |
$0.81B |
$10.33B |
8.02% |
| 2016-03-31 |
$0.81B |
$10.28B |
8.18% |
| 2015-12-31 |
$0.85B |
$9.77B |
8.88% |
| 2015-09-30 |
$0.84B |
$9.82B |
10.62% |
| 2015-06-30 |
$0.91B |
$9.57B |
14.41% |
| 2015-03-31 |
$0.87B |
$9.09B |
18.19% |
| 2014-12-31 |
$0.93B |
$3.28B |
28.09% |
| 2014-09-30 |
$0.92B |
$3.41B |
28.50% |
| 2014-06-30 |
$0.58B |
$3.35B |
18.21% |
| 2014-03-31 |
$0.63B |
$3.19B |
20.54% |
| 2013-12-31 |
$0.62B |
$2.96B |
20.76% |
| 2013-09-30 |
$0.61B |
$3.23B |
19.52% |
| 2013-06-30 |
$0.66B |
$2.95B |
20.54% |
| 2013-03-31 |
$0.62B |
$2.89B |
18.95% |
| 2012-12-31 |
$0.64B |
$3.36B |
18.37% |
| 2012-09-30 |
$0.61B |
$3.62B |
17.24% |
| 2012-06-30 |
$0.55B |
$3.20B |
15.85% |
| 2012-03-31 |
$0.56B |
$3.78B |
15.31% |
| 2011-12-31 |
$0.54B |
$3.51B |
14.49% |
| 2011-09-30 |
$0.41B |
$3.49B |
11.00% |
| 2011-06-30 |
$0.36B |
$3.88B |
9.65% |
| 2011-03-31 |
$0.27B |
$3.92B |
7.57% |
| 2010-12-31 |
$0.22B |
$3.62B |
6.70% |
| 2010-09-30 |
$0.22B |
$3.54B |
6.98% |
| 2010-06-30 |
$0.08B |
$2.98B |
2.46% |
| 2010-03-31 |
$0.08B |
$3.18B |
2.70% |
| 2009-12-31 |
$0.09B |
$3.15B |
3.16% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$14.478B |
$15.427B |
|
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
|
